Tests lowering blood pressure to slow brain white matter lesions in older adults
Tests lowering blood pressure in older adults with memory complaints and brain white matter lesions.
Plain-language title generated from the registry record
Registry title: Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
Key facts
- Where
- Bordeaux and Paris, FranceSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 88 years old?
Source: NCT02472028, who can take part
Where in France
- Memory for Research and Resources Center / Neuroscience poleBordeaux, FranceNot yet recruiting
- Memory Resources Centre and South of Ile de France Search - Broca HospitalParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT02472028
- Record updated
- 29 October 2026
- Original description
The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.Read full original descriptionShow less
LEukoaraiosis and blOod Pressure Reduction in OLD People
The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.
Inclusion: 60 to 88 years old patients; Patient with cognitive complaint with MMSE ≥ 20performed within 6 months prior to enrollment (with or without dementia); Patient with a socio-educational level ≥ 3; Presence of hyperintensities of moderate to high grade on the last MRI or old scan (grades C and D on the modified Scheltens scale, grades 2/3 Fazekas); Hypertension defined by a Systolic Blood Pressure (SBP) and / or a Diastolic Blood Pressure (DBP) ≥ 140/90 mmHg, treated or not; Affiliation to a social security system; Informed consent given, signed consent.
Exclusion: Patient already receiving 4 or more antihypertensive drugs at maximum dosage; Patient participating in another clinical research study on drug requiring exclusion period; Contraindication to MRI (presence of ferromagnetic foreign body (especially some intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis), subject carrying pacemaker, claustrophobic participants); Severe diseases associated with a life expectancy of less than 3 months; Presence of another dementia different than Alzheimer's disease vascular dementia or mixed dementia,; Secondary hypertension: renovascular hypertension, primary aldosteronism, pheochromocytoma ; severe renal impairment; Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP standing within 3 minutes; Major physical impairments that can interfere with the feasibility of the tests (sight, hearing ...); Persons under guardianship.